Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer

Irreversible electroporation (IRE) is a novel local tumor ablation approach with the potential to stimulate an antitumor immune response. However, it is not effective in preventing distant metastasis in isolation. This study aimed to compare the potential of augmenting the antitumor immune response in patients with locally advanced pancreatic cancer (LAPC) who underwent IRE combined with chemotherapy and PD-1/PD-L1 blockade with those who underwent IRE combined with chemotherapy.A retrospective review was conducted on LAPC patients treated either with IRE in combination with chemotherapy and PD-1/PD-L1 blockade (group A) or with IRE with chemotherapy alone (group B) from July 2015 to June 2021. The primary outcomes were overall survival (OS) and progression-free survival (PFS), with immune responses and adverse events serving as secondary endpoints. Risk factors for OS and PFS were identified using univariate and multivariate analyses.A total of 103 patients were included in the final analysis, comprising 25 in group A and 78 in group B. The median duration of follow-up was 18.2 months (3.0–38.6 months). Group A patients demonstrated improved survival compared to group B (median OS: 23.6 vs. 19.4 months, p = 0.001; median PFS: 18.2 vs. 14.7 months, p = 0.022). The data suggest a robust immune response in group A, while adverse events related to the treatment were similar in both groups. The multivariate analysis identified the combination of IRE, chemotherapy, and PD-1/PD-L1 blockade as an independent prognostic factor for OS and PFS.The addition of PD-1/PD-L1 blockade to the regimen of IRE combined with chemotherapy enhanced antitumor immunity and extended survival in LAPC patients.

[1]  H. Jacob,et al.  ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION VERSUS SURGICAL RESECTION FOR TREATMENT OF PANCREATIC INSULINOMA. , 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Jianxiang Shi,et al.  Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients , 2022, Molecular Medicine.

[3]  Y. Lv,et al.  Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors , 2022, Frontiers in immunology.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  Jiajia Guan,et al.  Immunomodulatory Effect of Irreversible Electroporation Alone and Its Cooperating With Immunotherapy in Pancreatic Cancer , 2021, Frontiers in Oncology.

[6]  Sheng-ping Li,et al.  Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer , 2021, Journal of inflammation research.

[7]  Yuqing Gu,et al.  Laparoscopic ultrasonography-guided cryoablation of locally advanced pancreatic cancer: a preliminary report , 2021, Japanese Journal of Radiology.

[8]  B. Davidson,et al.  Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy , 2021, Journal of clinical medicine.

[9]  L. Matrisian,et al.  Estimated Projection of US Cancer Incidence and Death to 2040 , 2021, JAMA network open.

[10]  N. Kalra,et al.  Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis , 2021, European Radiology.

[11]  Mao Lin,et al.  Chemotherapy plus concurrent irreversible electroporation improved local tumor control in unresectable hilar cholangiocarcinoma compared with chemotherapy alone , 2021, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[12]  Yanli Xing,et al.  Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer , 2020, World journal of clinical cases.

[13]  Johannes Crezee,et al.  HyCHEED System for Maintaining Stable Temperature Control during Preclinical Irreversible Electroporation Experiments at Clinically Relevant Temperature and Pulse Settings , 2020, Sensors.

[14]  T. Gress,et al.  The Immune Microenvironment in Pancreatic Cancer , 2020, International journal of molecular sciences.

[15]  C. Bassi,et al.  US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience , 2020, Ultraschall in der Medizin - European Journal of Ultrasound.

[16]  Robert C. G. Martin,et al.  A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. , 2020, Surgery.

[17]  Yu Zhang,et al.  T‐cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer , 2020, Clinical and translational medicine.

[18]  D. Miklavčič,et al.  High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. , 2020, Radiology.

[19]  G. Kazemier,et al.  Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation , 2019, Oncoimmunology.

[20]  Robert C. G. Martin,et al.  A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[21]  S. McKenna,et al.  Electrochemotherapy Causes Caspase-Independent Necrotic-Like Death in Pancreatic Cancer Cells , 2019, Cancers.

[22]  Sanjay Gupta,et al.  Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer , 2019, Nature Communications.

[23]  Robert C. G. Martin,et al.  Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma , 2019, Annals of Surgical Oncology.

[24]  E. Jaffee,et al.  Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. , 2018, JCI insight.

[25]  C. Bassi,et al.  Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. , 2018, Translational gastroenterology and hepatology.

[26]  T. Vogl,et al.  Microwave ablation of pancreatic tumors , 2018, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[27]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[28]  W. Burns,et al.  Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis , 2017, Annals of Surgical Oncology.

[29]  Robert C. G. Martin,et al.  CT Findings of Patients Treated with Irreversible Electroporation for Locally Advanced Pancreatic Cancer , 2015, Journal of oncology.

[30]  S. Chalikonda,et al.  Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. , 2015, Annals of surgery.

[31]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[32]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[33]  D. Santini,et al.  A prospective study on radiofrequency ablation locally advanced pancreatic cancer. , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[34]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[35]  G. Kazemier,et al.  Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. , 2019, Radiology.